Pharmacoeconomic Evaluation of Enalapril Folic Acid Tablet and Enalapril Tablet for Stroke Prevention in Patients with Hypertension
- VernacularTitle:依那普利叶酸片与依那普利片预防高血压患者卒中的药物经济学评价
- Author:
Yu REN
1
,
2
;
Xin GUAN
1
,
2
;
Yao ZHANG
1
,
2
;
Aixia MA
1
Author Information
1. School of International Pharmaceutical Business，China Pharmaceutical University，Nanjing 211198，China
2. Pharmacoeconomic Evaluation Research Center，China Pharmaceutical University，Nanjing 211198，China
- Publication Type:Journal Article
- Keywords:
Prevention;
Stroke;
Pharmacoeconomics;
Enalapril folic acid tablet;
Enalapril tablet;
Hypertension;
Health system
- From:
China Pharmacy
2021;32(23):2880-2884
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE：To evaluate the pharmacoec onomics of Enalapril folic acid tablet and Enalapril tablet for stroke prevention in patients with hypertension. METHODS ：Markov model was constructed by using Excel 2016 software. Patients with essential hypertension were selected as the research object with 1 year cycle and 20 years horizon. From the perspective of health system，the pharmacoeconomics of Enalapril folic acid tablets versus Enalapril tablets for stroke prevention in patients with hypertension was compared by cost-effectiveness analysis ，and the stability of the research results was verified by sensitivity analysis. RESULTS ：Compared with Enalapril tablet ，the incremental cost-effectiveness ratio of Enalapril folic acid tablet was 221 323 yuan/QALY，which was higher than three times of China ’s per capita GDP in 2020（217 341.04 yuan）. The results of single factor sensitivity analysis and probabilistic sensitivity analysis were consistent with that of basic analysis. CONCLUSIONS ： Compared with Enalapril tablet ，Enalapril folic acid tablet doesn ’t have a better economy for patients with hypertension.
